Sivik Global Healthcare LLC Has $2.80 Million Position in Amedisys Inc (AMED)

Sivik Global Healthcare LLC increased its stake in shares of Amedisys Inc (NASDAQ:AMED) by 28.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,607 shares of the health services provider’s stock after buying an additional 10,000 shares during the quarter. Sivik Global Healthcare LLC owned 0.13% of Amedisys worth $2,802,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AMED. Russell Investments Group Ltd. lifted its position in shares of Amedisys by 77.7% during the 1st quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock worth $1,854,000 after buying an additional 15,875 shares during the period. Great West Life Assurance Co. Can lifted its position in shares of Amedisys by 8.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock worth $2,045,000 after buying an additional 2,960 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Amedisys by 125.0% during the 1st quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock worth $39,915,000 after buying an additional 433,956 shares during the period. Suntrust Banks Inc. lifted its position in shares of Amedisys by 2.0% during the 1st quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares during the period. Finally, Comerica Bank lifted its position in shares of Amedisys by 4.2% during the 1st quarter. Comerica Bank now owns 30,909 shares of the health services provider’s stock worth $1,670,000 after buying an additional 1,258 shares during the period. Institutional investors and hedge funds own 96.80% of the company’s stock.

Amedisys Inc (AMED) traded down 1.42% during midday trading on Friday, reaching $52.03. The company had a trading volume of 454,262 shares. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $65.91. The stock has a market cap of $1.76 billion, a P/E ratio of 44.47 and a beta of 0.84. The firm has a 50-day moving average of $50.02 and a 200-day moving average of $54.86.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The firm had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. During the same period in the prior year, the company earned $0.42 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. On average, equities analysts expect that Amedisys Inc will post $2.21 EPS for the current fiscal year.

In other Amedisys news, Director Bruce D. Perkins bought 2,000 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was purchased at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the purchase, the director now directly owns 15,825 shares of the company’s stock, valued at $737,445. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

Several equities analysts recently commented on the company. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $60.00 target price on shares of Amedisys in a research report on Friday. Bank of America Corporation assumed coverage on Amedisys in a research report on Monday, August 21st. They set a “neutral” rating and a $55.00 target price for the company. BidaskClub upgraded Amedisys from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Mizuho downgraded Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Wednesday, July 26th. Finally, Royal Bank Of Canada restated a “hold” rating and set a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $56.44.

ILLEGAL ACTIVITY NOTICE: This story was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://transcriptdaily.com/2017/09/17/sivik-global-healthcare-llc-has-2-80-million-position-in-amedisys-inc-amed.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply